Vertex gets good news ahead of schedule
Everyone expected Vertex Pharmaceuticals to win approval for its latest cystic fibrosis treatment. No one expected it to happen in 2019.
Yesterday, the FDA approved Vertex’s Trikafta just three months after the company submitted it for review. The decision is five months ahead of schedule and marks one of the quickest FDA turnarounds in recent memory.
With the addition of Trikafta, Vertex now has a genetically defined therapy for roughly 90% of all patients with cystic fibrosis. And it has an enviable financial position. The company already banks nearly $4 billion each year from its portfolio of cystic fibrosis drugs, and analysts expect that figure to approach $7 billion by 2025.
Read more.
Yesterday, the FDA approved Vertex’s Trikafta just three months after the company submitted it for review. The decision is five months ahead of schedule and marks one of the quickest FDA turnarounds in recent memory.
With the addition of Trikafta, Vertex now has a genetically defined therapy for roughly 90% of all patients with cystic fibrosis. And it has an enviable financial position. The company already banks nearly $4 billion each year from its portfolio of cystic fibrosis drugs, and analysts expect that figure to approach $7 billion by 2025.
Read more.
.png)
No hay comentarios:
Publicar un comentario